What are the side effects of voriconazole?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Voriconazole

Voriconazole has a wide range of potential side effects, with visual disturbances, hepatotoxicity, and photosensitivity reactions being the most common adverse events requiring monitoring and potential dose adjustments. 1, 2

Common Side Effects

Visual Disturbances

  • Transient visual disturbances occur in approximately 30% of patients 1, 3
  • Typically manifest as photopsia (seeing flashes of light), color vision changes, and photophobia 1
  • Usually self-limited and reversible, not clearly associated with absolute drug levels 1
  • Occur early in treatment and resolve after discontinuation 3

Hepatotoxicity

  • Mild hepatotoxicity is common and related to drug concentration 1
  • Manifests as elevated liver enzymes (ALT, AST), alkaline phosphatase, and bilirubin 1, 3
  • Risk increases with voriconazole trough concentrations >3.61 mg/L 4
  • Occurs in 66.7% of patients within 7 days and 94.4% within 15 days of starting therapy 4
  • Severe hepatotoxicity is uncommon but requires careful monitoring 1
  • Patients with pre-existing liver dysfunction are at higher risk 5

Dermatologic Reactions

  • Photosensitivity reactions occur in approximately 20% of patients 6
  • Skin rash, erythroderma, and perioral excoriations 1
  • Long-term use associated with increased risk of squamous cell carcinoma and melanoma, especially in fair-skinned persons and immunosuppressed patients 1, 2, 7
  • Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported 3

Neurological Side Effects

  • Reversible central and peripheral neurologic symptoms 1
  • Visual or auditory hallucinations (2.4% of patients) 1, 3
  • Encephalopathy and peripheral neuropathy with prolonged use 7
  • Neurological side effects correlate with higher drug concentrations 1, 4

Cardiovascular Side Effects

  • QT interval prolongation on electrocardiography 1, 2
  • Tachyarrhythmias 1
  • Rare cases of ventricular arrhythmias (including torsade de pointes), bradycardia, cardiac arrest, and sudden death 1, 3
  • Higher risk in patients with history of cardiotoxic chemotherapy, cardiomyopathy, hypokalemia, or concomitant QT-prolonging medications 1

Gastrointestinal Side Effects

  • Nausea (5.4% of patients) 3
  • Vomiting (4.4% of patients) 3
  • Diarrhea 3

Long-Term Use Complications

  • Periostitis with severe pain in bones or joints associated with elevated serum fluoride levels 1, 2, 7
  • Squamous cell carcinoma and melanoma in sun-exposed areas 1, 2, 7
  • Alopecia and nail changes 7

Monitoring Recommendations

Therapeutic Drug Monitoring

  • Target trough concentrations: >1-1.5 μg/mL for efficacy and <5-6 μg/mL to minimize toxicity 1, 2
  • Monitoring is essential due to:
    1. Nonlinear pharmacokinetics in adults
    2. High interpatient variability due to CYP2C19 polymorphisms (especially common in Asian populations) 1, 2, 4
    3. Numerous drug-drug interactions 1, 2

Specific Monitoring

  • Baseline and periodic liver function tests 2
  • Regular skin examinations for patients on long-term therapy 2, 7
  • ECG monitoring in patients with cardiac risk factors or on other QT-prolonging medications 2
  • Visual symptom assessment 2

Risk Factors for Increased Toxicity

  • Genetic polymorphisms in CYP2C19 (more common in non-Indian Asian populations) 1
  • Concomitant medications that interact with CYP2C19 and CYP3A4 1, 2
  • Pre-existing liver dysfunction 5
  • Higher voriconazole trough concentrations 1, 4
  • Loading doses >300 mg (4.5 mg/kg) in patients with severe liver dysfunction 5

Practical Considerations

  • Consider oral formulation for patients with creatinine clearance <50 mL/min due to potential accumulation of cyclodextrin vehicle in IV formulation 1, 6
  • Advise patients to avoid direct sunlight and use sun protection to minimize photosensitivity reactions 2
  • Timely dose adjustments based on drug levels can prevent or mitigate hepatotoxicity 4

By understanding and monitoring for these side effects, clinicians can optimize the safety profile of voriconazole while maintaining its therapeutic efficacy in treating fungal infections.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Voriconazole Therapy Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Voriconazole hepatotoxicity in severe liver dysfunction.

The Journal of infection, 2013

Research

Voriconazole.

Clinical therapeutics, 2003

Research

Adverse effects of voriconazole: Over a decade of use.

Clinical transplantation, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.